Sestrin2 remedies podocyte injury via orchestrating TSP-1/TGF-β1/Smad3 axis in diabetic kidney disease

[1]  D. Bogenhagen,et al.  Loss of Functional SCO2 Attenuates Oxidative Stress in Diabetic Kidney Disease. , 2021, Diabetes.

[2]  C. Dai,et al.  Complement factor B in high glucose–induced podocyte injury and diabetic kidney disease , 2021, JCI insight.

[3]  Ming Wu,et al.  Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy. , 2021, Metabolism: clinical and experimental.

[4]  R. DeFronzo,et al.  Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors , 2021, Nature Reviews Nephrology.

[5]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.

[6]  Yi Fu,et al.  Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism. , 2020, Cell metabolism.

[7]  G. Laverman,et al.  Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. , 2020, The lancet. Diabetes & endocrinology.

[8]  G. Ding,et al.  Sestrin-2 regulates podocyte mitochondrial dysfunction and apoptosis under high-glucose conditions via AMPK , 2020, International journal of molecular medicine.

[9]  Wanqing Sun,et al.  The Emerging Role of Sestrin2 in Cell Metabolism, and Cardiovascular and Age-Related Diseases , 2020, Aging and disease.

[10]  L. Truong,et al.  Drp1S600 phosphorylation regulates mitochondrial fission and progression of nephropathy in diabetic mice. , 2019, The Journal of clinical investigation.

[11]  W. Foulsham,et al.  Thrombospondin-1 in ocular surface health and disease. , 2019, The ocular surface.

[12]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[13]  Yu-Ting Huang,et al.  A KDM6A–KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction , 2019, EMBO molecular medicine.

[14]  H. Duan,et al.  Thioredoxin‐interacting protein deficiency alleviates phenotypic alterations of podocytes via inhibition of mTOR activation in diabetic nephropathy , 2019, Journal of cellular physiology.

[15]  Yaoming Xue,et al.  MiR‐4756 promotes albumin‐induced renal tubular epithelial cell epithelial‐to‐mesenchymal transition and endoplasmic reticulum stress via targeting Sestrin2 , 2018, Journal of cellular physiology.

[16]  V. Nair,et al.  FSGS as an Adaptive Response to Growth-Induced Podocyte Stress. , 2017, Journal of the American Society of Nephrology : JASN.

[17]  J. He,et al.  A Novel Inhibitor of Homeodomain Interacting Protein Kinase 2 Mitigates Kidney Fibrosis through Inhibition of the TGF-β1/Smad3 Pathway. , 2017, Journal of the American Society of Nephrology : JASN.

[18]  H. Abboud,et al.  mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes. , 2016, Antioxidants & redox signaling.

[19]  Hai-Bo Long,et al.  Metadherin facilitates podocyte apoptosis in diabetic nephropathy , 2016, Cell Death and Disease.

[20]  T. Pihlajaniemi,et al.  Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences , 2015, Redox biology.

[21]  Qi Zhou,et al.  Interaction of thrombospondin1 and CD36 contributes to obesity-associated podocytopathy. , 2015, Biochimica et biophysica acta.

[22]  Jian-Kang Chen,et al.  EGF receptor deletion in podocytes attenuates diabetic nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[23]  C. R. Bagnell,et al.  Low TGFβ1 expression prevents and high expression exacerbates diabetic nephropathy in mice , 2015, Proceedings of the National Academy of Sciences.

[24]  I. G. Fantus,et al.  Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[25]  S. Shankland,et al.  Expression of a novel stress-inducible protein, sestrin 2, in rat glomerular parietal epithelial cells. , 2014, American journal of physiology. Renal physiology.

[26]  N. Frangogiannis,et al.  The role of thrombospondin (TSP)-1 in obesity and diabetes , 2014, Adipocyte.

[27]  F. Grahammer,et al.  The podocyte slit diaphragm—from a thin grey line to a complex signalling hub , 2013, Nature Reviews Nephrology.

[28]  A. Eid,et al.  Sestrin 2 and AMPK Connect Hyperglycemia to Nox4-Dependent Endothelial Nitric Oxide Synthase Uncoupling and Matrix Protein Expression , 2013, Molecular and Cellular Biology.

[29]  T. Benzing,et al.  The role of the podocyte in albumin filtration , 2013, Nature Reviews Nephrology.

[30]  Tetsuhiro Tanaka,et al.  Angiogenesis and hypoxia in the kidney , 2013, Nature Reviews Nephrology.

[31]  G. King,et al.  Vascular complications of diabetes: mechanisms of injury and protective factors. , 2013, Cell metabolism.

[32]  T. B. Huber,et al.  How many ways can a podocyte die? , 2012, Seminars in nephrology.

[33]  J. Boffa,et al.  Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. , 2012, Kidney international.

[34]  Feng-Sheng Wang,et al.  Modulation of Notch-1 Signaling Alleviates Vascular Endothelial Growth Factor–Mediated Diabetic Nephropathy , 2010, Diabetes.

[35]  Mark H. Ellisman,et al.  Sestrin as a Feedback Inhibitor of TOR That Prevents Age-Related Pathologies , 2010, Science.

[36]  Youhua Liu.  New insights into epithelial-mesenchymal transition in kidney fibrosis. , 2010, Journal of the American Society of Nephrology : JASN.

[37]  C. Daniel,et al.  Thrombospondin in Renal Disease , 2009, Nephron Experimental Nephrology.

[38]  Michael Karin,et al.  p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling , 2009, Cell.

[39]  J. Kreidberg,et al.  Development of the renal glomerulus: good neighbors and good fences , 2008, Development.

[40]  Youhua Liu,et al.  Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. , 2008, The American journal of pathology.

[41]  T. Berl,et al.  Pathogenesis of Diabetic Nephropathy , 2004, Reviews in Endocrine and Metabolic Disorders.

[42]  E. Schrama,et al.  Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane , 1994, Diabetologia.

[43]  A. Chajut,et al.  Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability , 2002, Oncogene.

[44]  M. Steffes,et al.  Glomerular cell number in normal subjects and in type 1 diabetic patients. , 2001, Kidney international.

[45]  R. Zeller,et al.  Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. , 1997, Experimental cell research.

[46]  W. Kriz,et al.  Synaptopodin: An Actin-associated Protein in Telencephalic Dendrites and Renal Podocytes , 1997, The Journal of cell biology.

[47]  T. Meyer,et al.  Podocyte loss and progressive glomerular injury in type II diabetes. , 1997, The Journal of clinical investigation.